EDIT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Editas Medicine Inc (EDIT) is not a good buy for a beginner investor with a long-term strategy at this time. The stock exhibits bearish technical indicators, weak financial performance, and lacks positive sentiment or catalysts to support a strong upward trajectory. Additionally, there are no Intellectia Proprietary Trading Signals to suggest a short-term trading opportunity.
The stock is showing bearish signals with the MACD histogram negatively expanding below 0, RSI at 27.648 indicating no clear signal, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The price is near the support level of 1.703, with resistance at 2.046. The stock has a high probability of further decline in the short term (-1.93% next day, -2.37% next week, -4.67% next month).
Hedge funds are significantly increasing their positions in the stock, with a 500.44% increase in buying over the last quarter.
No recent news or event-driven catalysts. Insider trading activity is neutral. The stock lacks momentum and has a high implied volatility (229.65%) with an IV percentile of 98, indicating potential risk. Additionally, the stock is underperforming with a -5.08% regular market change.
In Q3 2025, revenue increased significantly by 12265.57% YoY to $7.54M, but net income dropped by -59.58% YoY to -$25.12M, and EPS declined by -62.67% YoY to -0.28. Gross margin remained flat at 100%. The financials indicate revenue growth but poor profitability and earnings performance.
No recent analyst rating or price target changes available.
